ARTICLE | Company News

ADCendo licenses ADCs from University of Copenhagen

November 10, 2017 9:26 PM UTC

Newco ADCendo ApS (Copenhagen, Denmark) received exclusive, worldwide rights to antibody-drug conjugates (ADCs) targeting mannose receptor C type 2 (MRC2) from the University of Copenhagen and the Capital Region of Denmark. ADCendo plans to use the ADCs to develop therapies for cancers including sarcomas and glioblastoma.

The university and the Capital Region of Denmark are eligible for milestones and royalties. ADCendo CEO Henrik Stage declined to disclose financial terms...